Aptevo Therapeutics Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; filed March 5, 2024. This is an annual report, not a standalone fourth-quarter filing. Aptevo is a clinical-stage biotechnology company developing cancer immunotherapies. It has two clinical-stage candidates, APVO436 and ALG.APV-527, and three preclinical candidates. It has no products approved for commercial distribution.
Financial results and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Royalty revenue | $0 | $3.1 million |
| Research and development expense | $17.1 million | $17.9 million |
| General and administrative expense | $11.8 million | $13.9 million |
| Operating loss | $28.9 million | $28.6 million |
| Net loss / income | $(17.4) million | $8.0 million |
| Cash used in operating activities | $11.7 million | $21.0 million |
| Cash and cash equivalents at year-end | $16.9 million | $22.6 million |
| Long-term debt | $0 | $3.5 million |
- FY2023 net loss included a $9.65 million gain from selling certain future IXINITY-related payments to XOMA. Aptevo repaid its remaining MidCap debt using part of the transaction proceeds.
- FY2022 net income was driven by a nonrecurring $37.2 million gain from extinguishing the HCR royalty-sale liability and $2.5 million of royalty-related milestone income; it is not a useful indicator of recurring profitability.
- Year-end total current assets were $19.1 million and current liabilities were $7.2 million. Total liabilities were $12.6 million, including $6.1 million of operating lease liabilities. The Seattle facility lease runs through April 2030.
- There are no meaningful product-sales margins to report; the filing reports no royalty revenue in 2023 and the company has no approved commercial products.
Material changes versus FY2022
- Net results shifted from $8.0 million income to a $17.4 million loss, largely reflecting the absence of FY2022’s exceptional royalty-liability gain and milestone income. Operating loss was broadly stable.
- Operating cash use decreased by $9.3 million. Cash nevertheless fell by $5.7 million during 2023, while financing activities provided $6.0 million, primarily from equity and warrant transactions.
- Aptevo received $9.65 million from XOMA for rights to all future deferred payments and specified portions of potential Medexus milestones. Aptevo retains eligibility for up to $5.8 million of other Medexus milestone payments.
- Common shares outstanding increased from 6.47 million at year-end 2022 to 19.47 million at year-end 2023; 23.47 million were outstanding on March 5, 2024. The filing also reports approximately 30.7 million warrants outstanding at year-end 2023.
Outlook, commentary, and key risks
- Going concern and funding: Management and the auditor report substantial doubt about Aptevo’s ability to continue as a going concern. Management states that available cash is insufficient to complete clinical development of any candidate and that additional funding is required. The filing does not provide a clear assured cash runway; management’s going-concern assessment covers one year from issuance of the financial statements. Funding plans include equity issuance, partnering or licensing assets, and debt financing, none of which is assured.
- Pipeline: Aptevo planned to begin a dose-optimization Phase 1b/2 study of APVO436 with venetoclax and azacitidine in frontline AML patients in the first half of 2024. ALG.APV-527’s Phase 1 solid-tumor trial, initiated in February 2023 with Alligator Bioscience, was enrolling patients. APVO603 and APVO442 remained in preclinical/IND-enabling work; APVO711 was preclinical.
- APVO436 safety and efficacy: The completed Phase 1b dose-expansion study reported the highest composite remission rate of 82% and CR/CRi rate of 73% in the 11 evaluable venetoclax-naïve patients in Cohort 2. Across 44 patients in the safety population, 12 developed cytokine release syndrome (CRS), mostly grade 1 or 2; one treatment-related grade 5 CRS event was reported, with sepsis and pneumonia complicating causality assessment. These early, open-label results are not proof of later-stage efficacy.
- Other risks and contingencies: Clinical failure, patient-enrollment or trial delays, adverse events, reliance on third-party manufacturers and CROs, competition, and inability to raise capital may impair development. Potential Medexus payments depend on its continued commercialization of IXINITY. Aptevo received a Nasdaq notice for bid-price noncompliance, with a stated compliance date of March 11, 2024; stockholders approved a possible 1-for-15 to 1-for-44 reverse split in February 2024. The filing reports no currently pending legal matter expected by management to materially affect results, financial condition, or cash flows.
Most important facts for investors to verify
- Current cash, actual operating cash burn, and whether subsequent financing or partnering provides adequate funding to address the disclosed going-concern uncertainty.
- Nasdaq bid-price compliance status and whether the Board implemented the approved reverse split.
- Subsequent warrant exercises, share issuances, and resulting dilution; the filing’s warrant overhang is substantial relative to year-end shares outstanding.
- Complete APVO436 trial results, including the grade 5 CRS event, and whether the planned combination trial began; also verify ALG.APV-527 enrollment and safety updates.
- Progress toward any remaining Medexus milestones and the terms and timing of payments retained after the XOMA transaction.